In a patient who is a survivor of Her2+ breast cancer with positive estrogen and progesterone receptors, could TIM3 be analyzed to prevent relapses?
Abstract
There is no current evidence directly linking TIM3 analysis to relapse prevention in HER2-positive, ER/PR-positive breast cancer, but it remains a potential target for further research.
Fields of Study & Subjects
HER2/EGFR in Cancer Research
Breast Cancer Treatment Studies
Cancer Immunotherapy and Biomarkers
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 9 February 2026